肢端肥大症治疗市场规模、份额和成长分析（按疾病类型、诊断类型、治疗类型和地区）- 产业预测 2025-2032

2023 年全球肢端肥大症治疗市场规模价值14 亿美元，预计将从2024 年的14.9 亿美元增长到2032 年的23.9 亿美元，预计在预测期内（2025-2032 年）到2032 年将达到14.9亿美元)。

由于肢端肥大症盛行率不断上升以及对创新治疗方法的需求不断增加，因此肢端肥大症治疗市场预计将出现强劲成长。研发投入的快速成长推动製药公司专注于创造新的药物配方和给药方法。遗传疾病的流行和生活方式的改变预计会推动这种需求，特别是随着荷尔蒙失调变得越来越普遍。特别是，强大的药品管道，包括预期 FDA核准的新型生长激素受体拮抗剂和生长抑制素类似物，可能会进一步提升市场的潜力。放射线手术等检测方法的技术进步将提高治疗效果并减少副作用。此外，政府针对罕见疾病的支持政策和计划可能会在未来几年促进市场的扩张。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

肢端肥大症治疗市场规模（依疾病类型）

• 市场概况
• 异位肢端肥大症
• 假性肢端肥大症

肢端肥大症治疗市场规模（依诊断类型）

• 市场概况
• 医学影像
• 实验室测试

肢端肥大症治疗市场规模（依治疗类型划分）

• 市场概况
• 外科手术
• 药物治疗
• 放射治疗

肢端肥大症治疗市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Novartis AG（Switzerland）
• Ipsen Pharma（France）
• Pfizer Inc.（USA）
• Crinetics Pharmaceuticals, Inc.（USA）
• Strongbridge Biopharma plc（Ireland）
• Ionis Pharmaceuticals, Inc.（USA）
• Merck & Co., Inc.（USA）
• AbbVie Inc.（USA）
• Eli Lilly and Company（USA）
• AstraZeneca PLC（UK）
• Sanofi SA（France）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Hikma Pharmaceuticals PLC（UK）
• Lupin Ltd.（India）
• Recordati SpA（Italy）
• Xeris Biopharma Holdings, Inc.（USA）
• Peptron Inc.（South Korea）

结论和建议

Global Acromegaly Treatment Market size was valued at USD 1.4 billion in 2023 and is poised to grow from USD 1.49 billion in 2024 to USD 2.39 billion by 2032, growing at a CAGR of 6.1% during the forecast period (2025-2032).

The acromegaly treatment market is poised for robust growth, driven by the rising incidence of the disease and the increasing demand for innovative therapies. With a surge in research and development investments, pharmaceutical companies are focused on creating new drug formulations and administration methods. The prevalence of hereditary conditions and lifestyle changes is expected to fuel this demand, especially as hormonal disorders become more common. Notably, a strong pharmacological pipeline, including anticipated FDA approvals for new growth hormone receptor antagonists and somatostatin analogues, will further elevate market potential. Technological advancements in detection methods like radiosurgery are set to enhance treatment efficacy and reduce side effects. Additionally, supportive government policies and programs for rare diseases will contribute to market expansion in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Acromegaly Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Acromegaly Treatment Market Segmental Analysis

Global Acromegaly Treatment Market is segmented by Disease Type, Diagnosis Type, Treatment Type and region. Based on Disease Type, the market is segmented into Ectopic Acromegaly and Pseudo Acromegaly. Based on Diagnosis Type, the market is segmented into Medical Imaging and Medical Laboratory Test. Based on Treatment Type, the market is segmented into Surgery, Drug Therapy and Radiation Therapy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Acromegaly Treatment Market

The acromegaly treatment market is predominantly driven by the rising incidence of acromegaly, a rare endocrine disorder characterized by an overproduction of growth hormone. As awareness surrounding the condition increases and diagnostic capabilities enhance, more individuals are being identified and treated for acromegaly. This growing recognition of the disease correlates with heightened demand for effective therapeutic solutions, stimulating advancements in treatment options. Consequently, the escalating prevalence of acromegaly significantly propels the market forward, creating opportunities for pharmaceutical companies to innovate and expand their offerings in this specialized healthcare sector as patient needs evolve.

Restraints in the Global Acromegaly Treatment Market

The Global Acromegaly Treatment market faces significant restraints, primarily due to limited awareness and underdiagnosis of the condition. Although acromegaly is becoming more prevalent, many cases remain undetected or are diagnosed later than ideal because the symptoms develop gradually and are often non-specific. This lack of awareness among healthcare professionals and the general public contributes to delays in diagnosis and treatment, ultimately hindering the growth of the market. Addressing these awareness gaps is crucial for facilitating early detection and improving patient outcomes in acromegaly treatment.

Market Trends of the Global Acromegaly Treatment Market

The Global Acromegaly Treatment market is increasingly trending towards targeted therapies, significantly reshaping treatment approaches. This shift is characterized by the rising adoption of somatostatin analogs and growth hormone receptor antagonists, which adeptly address the underlying hormonal imbalances that contribute to acromegaly. By providing enhanced efficacy and improved tolerability compared to traditional treatments, these innovative therapies cater to the growing demand for personalized medicine. As awareness and diagnosis rates of acromegaly rise, coupled with advancements in pharmaceutical research, the market is projected to expand, driven by the continued development and commercialization of these specialized treatment options.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Acromegaly Treatment Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Ectopic Acromegaly
• Pseudo Acromegaly

Global Acromegaly Treatment Market Size by Diagnosis Type & CAGR (2025-2032)

• Market Overview
• Medical Imaging
• Medical Laboratory Test

Global Acromegaly Treatment Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Surgery
• Drug Therapy
• Radiation Therapy

Global Acromegaly Treatment Market Size & CAGR (2025-2032)

• North America (Disease Type, Diagnosis Type, Treatment Type)
  • US
  • Canada
• Europe (Disease Type, Diagnosis Type, Treatment Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Diagnosis Type, Treatment Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Diagnosis Type, Treatment Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Diagnosis Type, Treatment Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Crinetics Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Strongbridge Biopharma plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recordati S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Xeris Biopharma Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Peptron Inc. (South Korea
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations